Trader’s Recap: Medivation, Inc. (NASDAQ:MDVN), Celator Pharmaceuticals, Inc. (NASDAQ:CPXX), Dominion Diamond Corporation (NYSE:DDC), Discovery Communications, Inc.

Medivation, Inc. (NASDAQ:MDVN) and Astellas Pharma Inc announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) that they have submitted for XTANDI®(enzalutamide) capsules in metastatic castration-resistant prostate cancer (mCRPC), which includes findings from the Phase 2 TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication. Enzalutamide is approved by the FDA for the treatment of patients with mCRPC. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is October 22, 2016.

Medivation, Inc. (NASDAQ:MDVN) belongs to Healthcare sector. Its net profit margin is 31.70% and weekly performance is -0.74%. On last trading day company shares ended up at $32.04. Medivation, Inc. (NASDAQ:MDVN) distance from 50-day simple moving average (SMA50) is -1.31%.

On 16 February, Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) announced that the Phase 3 clinical trial of VYXEOS™ Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival. The company expects to announce overall survival results later this quarter.

Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) shares fell -5.29% in last trading session and ended the day at $2.15. CPXX return on assets is -53.40%. Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) quarterly performance is 22.86%.

Dominion Diamond Corporation (NYSE:DDC) recorded total fourth quarter sales of $178.1 million ($240.6 million in Q4 fiscal 2015). For fiscal year 2016, the Company recorded sales of $720.6 million ($915.7 million in fiscal 2015).

On 24 February, Dominion Diamond Corporation (NYSE:DDC) shares fell -3.98% and was closed at $10.38. DDC EPS growth in last 5 year was 31.00%. Dominion Diamond Corporation (NYSE:DDC) year to date (YTD) performance is 1.47%.

Discovery Communications, Inc. (NASDAQ:DISCA) said that, its Chief Financial Officer Andrew Warren has decided to leave the company.

Discovery Communications, Inc. (NASDAQ:DISCA) ended the last trading day at $25.20. Company weekly volatility is calculated as 4.33% and price to cash ratio as 26.23. Discovery Communications, Inc. (NASDAQ:DISCA) showed a weekly performance of -5.65%.

Zacks Investment Research lowered shares of Ocera Therapeutics Inc (NASDAQ:OCRX) from a hold rating to a sell rating in a research report sent to investors on Tuesday, Marketbeat.com reports.

Ocera Therapeutics, Inc. (NASDAQ:OCRX) shares fell -6.23% in last trading session and ended the day at $2.86. OCRX return on assets is -65.80%. Ocera Therapeutics, Inc. (NASDAQ:OCRX) quarterly performance is -19.89%.

Leave a Reply

Your email address will not be published. Required fields are marked *